Radius Health (RDUS) : The total negative money flow of $4.57 million on Wednesday indicates selling on strength. The inflow of money on upticks was $33.59 million, compared to $38.16 million outflow on downticks, which confirms distribution in the stock. The up to down ratio was 0.88. The negative money flow of $2.35 million in block trades reveals that the informed traders sold the stock on every bit of price strength. The traded value of the stock on uptick was $3.53 million in a block trade.The transaction value of block trade on downtick was $5.89 million. The uptick to downtick ratio was 0.6. The price action in the Radius Health (RDUS) stock suggests that both the bulls and the bears were in equilibrium. The stock traded at $58.13 with a gain of $1.28 , a change of 2.25% over the previous days close. The stock registered 2.85% for the week.
Shares of Radius Health, Inc. rose by 2.31% in the last five trading days and 6.58% for the last 4 weeks. Radius Health, Inc. is up 57.19% in the last 3-month period. Year-to-Date the stock performance stands at -5.54%.
Radius Health (RDUS) : The consensus on Radius Health (RDUS) based on 6 analyst recommendation on the company stock is 1.67, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Radius Health (NASDAQ:RDUS): The stock opened at $57.1 and touched an intraday high of $59.22 on Wednesday. During the day, the stock corrected to an intraday low of $55.86, however, the bulls stepped in and pushed the price higher to close in the green at $58.13 with a gain of 2.25% for the day. The total traded volume for the day was 2,375,730. The stock had closed at $56.85 in the previous trading session.
Radius Health, Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, as well as other serious endocrine-mediated diseases. The Companys lead product candidate is abaloparatide (BA058), a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection, which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch, which the Company refers to as abaloparatide-TD. The Companys clinical product portfolio also includes the investigational drug RAD1901, a selective estrogen receptor down regulator/degrader (SERD) and RAD140, a nonsteroidal selective androgen receptor modulator (SARM), for the treatment of breast cancer.